Diphtheria tetanus pertussis-hepatitis B vaccine - GSK
Alternative Names: Diphtheria-tetanus-pertussis-hep B vaccine (Tritanrix-HepB) - GSK; DPT + Hepa B vaccine - GSK; DTPw-HBV vaccine - GSK; Tritanrix HB - GSK; Tritanrix HepB; Tritanrix-HepBLatest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Bacterial vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Hepatitis B; Pertussis; Tetanus
Most Recent Events
- 20 Dec 2013 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts a positive scientific opinion in accordance with Article 58 of Regulation (EC) No 726/2004 for Tritanrix® HB for immunisation against diphtheria, tetanus pertussis and hepatitis B in infants from 6 weeks onwards
- 05 May 2011 Launched for Diphtheria in India (IM)
- 05 May 2011 Launched for Diphtheria in Vietnam (IM)